

May 12, 2023

## **Signed Informed Consent Form**

**Title:** Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation and Chronic Kidney Disease

Number ID: 00630186

### ***Statement of informed consent***

The databases were linked through encrypted personal health numbers. We have access to RAMQ administrative database, where no patient or physician identifiers were provided to the researchers; only scrambled identifiers were used throughout the study. Data access requests for the RAMQ databases are approved by the *Commission d'accès à l'information du Québec*. All efforts were made to maintain the data confidentiality. Information from these databases provided a comprehensive picture of hospitalizations.

This research was based on information extracted from user files without interactions with the research participants in accordance with the provisions of Section 125 of the Act respecting access to documents held by public bodies and the protection of personal information (L.R.Q c. A-2.1; public sector law) and Section 21 of the Act respecting the protection of personal information in the private sector (L.R.Q c. P-39.1; private sector law). Permission to receive the data used for this research was obtained by the *Commission de l'accès à l'information du Québec* and the research protocol received the approval of the University of Montreal Ethics Committee appointed *Comité d'éthique de la recherche en sciences et en santé*. The informed consent is waived by the ethics committee of the University of Montreal Ethics Committee appointed *Comité d'éthique de la recherche en sciences et en santé* and *Commission de l'accès à l'information du Québec*.

All authors contributed to the study conception, design and interpretation of data. All authors read and approved the final manuscript. Given that M. Dorais is founder of StatSciences Inc., this commercial affiliation had a role in data collection (executing patient selection and associated analyses from the original cohort with the assistance of Dr. Perreault) and providing M. Dorais with a salary.

**Sylvie Perreault**, Professor, Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.

I agree with the statement

Name: Sylvie Perreault

Signature: 

**Laurie-Anne Boivin-Proulx**, MD, MSc, FRCPS University of Montreal Hospital  
Research Centre (CRCHUM), Montreal, Quebec, Canada

I agree with the statement


Name: Laurie-Anne Boivin-Proulx

Signature: 

**Aurélie Lenglet**, Professor, Faculty of Pharmacy, EA 7517, Laboratory MP3CV, Jules  
Verne University of Picardie, Amiens, France. Department of Pharmacy, Amiens  
Picardie University Medical Center, Amiens, France

I agree with the statement

Name: Aurélie Lenglet

Signature: 

**Ziad A. Massy**, Professor, INSERM U-1018, Research Center in Epidemiology and  
Population Health (CESP), Team 5, Paris-Saclay University (PSU) and University of  
Paris Ouest -Versailles-Saint-Quentin-en-Yvelines (UVSQ), Villejuif, France. Division  
of Nephrology, AP-HP Ambroise-Paré Hospital, Boulogne Billancourt/Paris, France

I agree with the statement

Name: Ziad A. Massy

Signature: 

**Marc Dorais**, President, StatSciences Inc., Notre-Dame-de-l'Île-Perrot, Montreal,  
Quebec, Canada

I agree with the statement

Name: Marc Dorais

Signature: 